Certain cancer rates are on the rise, and outcome inequities remain a major public health concern. Getting into clinical trials is difficult, care is fragmented and treatments can be prohibitively expensive. Meanwhile, research for many cancers is underfunded.
The American Cancer Society is on a mission to end cancer as we know it. Its venture capital and impact investment arm, BrightEdge, invests in early-stage companies developing therapeutics, diagnostics, devices and technologies that share in this goal.
In this week’s episode of “Podnosis,” Fierce Healthcare’s Anastassia Gliadkovskaya chats with BrightEdge’s managing director Alice Pomponio about how the organization leans into its expertise in research, patient support and advocacy when working with entrepreneurs, what it looks for in emerging companies and how it measures their impact.
To learn more about the topics in this episode:
Publisher: Source link
